Bi-HPDO3A as a novel contrast agent for X-ray computed tomography

Rebecca Rizzo; Martina Capozza; Carla Carrera; Enzo Terreno

doi:10.1038/s41598-023-43031-y

Bi-HPDO3A as a novel contrast agent for X-ray computed tomography

Sci Rep. 2023 Oct 5;13(1):16747. doi: 10.1038/s41598-023-43031-y.

Authors

Rebecca Rizzo¹, Martina Capozza¹, Carla Carrera², Enzo Terreno³

Affiliations

¹ Department of Molecular Biotechnology and Health Sciences, Molecular Imaging Centre, University of Torino, Via Nizza 52, 10126, Turin, Italy.
² Institute of Biostructures and Bioimaging, National Research Council, Via Nizza 52, 10126, Turin, Italy.
³ Department of Molecular Biotechnology and Health Sciences, Molecular Imaging Centre, University of Torino, Via Nizza 52, 10126, Turin, Italy. enzo.terreno@unito.it.

Abstract

A new bismuth-based CT agent was synthesized through a facile synthesis strategy. The in vitro stability, toxicity and CT performance were evaluated. The in vivo imaging performance was investigated using three different doses (0.5, 1.2 and 5 mmol/kg) and the result obtained at 1.2 mmol/kg was compared with the clinically approved CT agent iopamidol at the same dosage.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Bismuth
Contrast Media*
Tomography, X-Ray Computed* / methods

Substances

Contrast Media
Bismuth